SCHEMBL6462707

SCHEMBL6462707

NC(=O)c1ccc(C2CCS(=O)(=O)c3ccccc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.37
CYP2C19 P33261 2/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
PARP1 P09874 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CYP2C9 P11712 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
ADRA1D P25100 1/20 0.36
HAO1 Q9UJM8 1/20 0.36
HSD11B1 P28845 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053425 0.87 HAO1 (0.39) TSHRMEN1KMT2AHAO1
SCHEMBL6462716 0.86 KDM1A (0.39) L3MBTL1CYP2C19POLBCYP3A4PARP1
SCHEMBL4441982 0.77 ADRA1D (0.33) ADRA1DSLC6A2SLC6A4SLC6A3
SCHEMBL30804967 0.74 IGF1R (0.36) MEN1KMT2AHAO1
SCHEMBL14360065 0.71 HAO1 (0.64) KMT2AADRA1DHAO1HSD11B1
SCHEMBL6490874 0.69 RAB9A (0.42) L3MBTL1MAPTTSHRHSD17B10TDP1
SCHEMBL2906600 0.69 CA2 (0.41) ADRA1DSLC6A2SLC6A4SLC6A3
SCHEMBL13499160 0.69 CA2 (0.41) ADRA1DSLC6A2SLC6A4SLC6A3
SCHEMBL1847062 0.68 ALDH1A1 (0.38) MAPTMEN1KMT2AADRA1D
Terephthalamide SCHEMBL27974622 0.68 KMT2A (0.59) L3MBTL1CYP2C19POLBCYP3A4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906053-B2 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-06-14 US disclosed
US-20040209874-A1 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) SHEPPECK JAMES E (US) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209874-A1 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) ADAM17, ADAMTS1, ADAM8 L3MBTL1 4310/4885CYP2C19 1502/4885POLB 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.